Once known as a paradigm changing class of precision oncology, or targeted, drugs,1 Bruton tyrosine kinase (BTK) inhibitors are now well established as treatment for several hematological malignancies. They are named for Lt Col Ogden C. Bruton, MD, chief of pediatrics at Walter Reed Army Medical Center in the 1950s, who in 1951 discovered the first host immunodeficiency in humans, X-linked agammaglobulinemia.2,3
The BTK protein is essential to helping B cells develop and mature into functional and specialized white blood cells; these are part of the adaptive immune response in producing antibodies, or immunoglobulins.4 But mutations in the BTK gene, more than 600 of which have been identified, can lead to a sizeable reduction in the number of circulating B cells, along with reduced ability to fight infection, absence of the BTK protein, production of abnormal BTK protein, or cancer cell growth.5,6
Mutated immunoglobulins essentially malfunction in their roles as antigen receptors on the surfaces of B cells, especially in the cancer space, by not recognizing antigens as damaging or by not sending the correct signals to destroy the malignant cells.
This is where BTK inhibitors come in: They help to trigger cell death by blocking the B-cell receptor signaling that leukemias and lymphomas use to grow and survive.7 The first-generation BTK inhibitor ibrutinib (Imbruvica) came to market in 2013, when it was approved by the FDA to treat adult patients with mantle cell lymphoma. A targeted treatment, it stops cancer cells from surviving and multiplying by blocking abnormal protein signaling.8 Other indications, as monotherapy or in combination, have been approved for chronic lymphocytic leukemia, Waldenstrm macroglobulinemia, small lymphocytic lymphoma, relapsed/refractory marginal zone lymphoma, and chronic graft-versus-host disease.9 Ibrutinib is a once-daily oral agent and can be used in the frontline and relapsed settings.10
Despite its many benefits and indications, however, ibrutinib as BTK inhibition is also associated with numerous adverse effects (AEs) on nonmalignant cells, which range from common to uncommon and from mild to severe, making ibrutinibs toxicity profile notorious.7
Among the most severe AEs are hemorrhage; high blood pressure; heart rhythm irregularities, including ventricular arrhythmias, atrial fibrillation, and atrial flutter; second primary cancers (eg, skin, other organs); and tumor lysis syndrome.11 Some of the most common AEs, occurring in more than 30% of patients, are hematological (eg, decreased platelets, neutrophils, and hemoglobin), musculoskeletal, and respiratory in nature.
Additional possible AEs include diarrhea, constipation, vomiting, skin infections, dizziness, dehydration, petechiae, arthralgia, stomatitis, rash, and fatigue.12 Ibrutinib carries warnings for use among those with bleeding problems, liver problems, and for those who are planning surgery or recently had surgery; women who are pregnant or thinking of becoming pregnant; women who breastfeed or plan to do so; and men with female partners capable of pregnancy.
Second-generation BTK inhibitors seek to improve upon first-generation agents like ibrutinib by having less cardiotoxicity, fewer AEs that result in stopping treatment, and fewer off-target effects. For example, ibrutinib inhibits the activity of 3 major off-targets: epidermal growth factor, which can result in severe skin toxicities13; interleukin-2 inducible kinase, which impairs natural killer cells cytotoxic abilities14; and the Tec family of kinases, decreasing their ability to aid in phosphorylation.15
In updated results of the ASPEN trial presented at this years virtual American Society of Clinical Oncology (ASCO) 2020 Annual Meeting, zanubrutinib (Brukinsa), the most recent second-generation BTK inhibitor to hit the US market, was shown to have a survival advantage over ibrutinib in patients with Waldenstrm macroglobulinemia who lacked the MYD88 mutation typically associated with successful treatment.16
ASPEN first compared zanubrutinib with ibrutinib in patients with Waldenstrm macroglobulinemia who have the MYD88 mutation, and zanubrutinib was shown in December 2019 to increase the incidence of complete response (CR) or very good partial response (VGPR) by close to 46% compared with ibrutinib28.9% vs 19.8%, respectivelyin patients with relapsed or refractory disease.17
The updated results, from 5 additional months of data, widened this gap, showing a 30.4% CR plus VGPR rate for zanubrutinib compared with 18.2% for ibrutinib, as well as less occurrence of atrial fibrillation/flutter of any grade, bleeding of any grade, major hemorrhage, diarrhea, and hypertension. In addition, patients without the MYD88 mutation had an overall response rate of 80.8%, which included a 50.0% major response ratewhich itself included a VGPR rate of 26.9%and 12-month progression-free survival of 72.4%.18
Lead investigator, Constantine Tam, MBBS, MD, a clinical hematologist and professor at the Peter MacCallum Cancer Centre in Victoria, Australia, noted of zanubrutinib, Those patients who potentially have a history of hypertension or have a history of atrial fibrillationor have an abnormal ECG or abnormal echocardiogrammaybe theyre the ones who would be better off on [zanubrutinib] compared with ibrutinib. We think its how clean the targeting is.19
Zanubrutinib is associated with less incidence of muscle spasm, peripheral edema, pneumonitis, and pneumonia. In essence, fewer overall AEs with second-generation BTK inhibitors means less of a need to reduce dosing and a greater likelihood of being able to stay on treatment longer. Tam noted that most AEs happen with zanubrutinib during the first year on treatment, before their incidence plateaus, whereas prolonged treatment with ibrutinib has a greater chance of inflicting cumulative damage to the vascular system.20 Compared with first-generation BTK inhibitors, the second-generation drugs are associated with fewer concerns about primary and acquired drug resistance. For example, ibrutinib use among patients with relapsed/refractory mantle cell lymphoma has been shown to both have no effect on the disease and have a negative impact on additional therapies.21
These resistance mechanisms of action are 2-fold. They are molecular, in that they involve sustained distal B-cell receptor signaling through PIK3-AKT (protein kinase B) pathway activation, NFkB pathway activation, and cell cycle progression. They also are therapeutic, in that lines of therapy administered after BTK inhibitors do not produce prolonged responses or exceptional overall survival.21
Less Cardiotoxicity in Second Generation
Some of the strongest gains in this newer generation of BTK inhibitors, however, can be seen in the cardiovascular space, when compared with the toxicities of the first-generation inhibitors
that often lead to treatment discontinuation, especially among older, sicker patients who have a history of cardiac disease. In fact, most BTK inhibitors are prescribed for older patients, because the class of drugs is used primarily to treat chronic lymphocytic leukemia, for which the average age of onset is older than 60 years.22
I think its that a lot of the toxicities are related to off-target effects, meaning the binding of the BTK inhibitor drug to receptors or molecules that are not the ones that that theyre supposed to be treating the cancer for, said Michael Kolodziej, MD, FACP, vice president and chief innovation officer, ADVI Health, in an interview with Evidence-Based Oncology.
The big ones that were identified with the first-generation inhibitors were cardiovascular, or hypertension and atrial arrhythmias, atrial fibrillation. And they were not rare side effects.
Kolodziej explained that the second-generation drugs have fewer off-target effectsless cardiovascular toxicity, atrial arrhythmias, and hypertensionbecause of their improved toxicity profile, largely because the drugs are just better at being BTK inhibitors. Its not any more complicated than that.
The chief challenge of the first-generation BTK inhibitors is that the AEs cause clinicians and patients to stop treatment with them, Kolodziej noted. The cancer does not become resistant, but the toxicities become unbearable and the patients become intolerant, he emphasized.
The thinking is that the reduced cardiovascular side effects, the reduced bleeding, are going to allow a better persistence on the second-generation drugs, he explained.
Tolerability and Payers
Indeed, in a pooled analysis of clinical trials of the second-generation BTK inhibitor acalabrutinib (Calquence), also presented in May at ASCO, lead author Richard R. Furman, MD, of Weill Cornell Medicine in New York, found that at a median follow-up of 26.4 months, 65% of patients were still on treatment. Of the 34% of patients who stopped acalabrutinib, half (17%) did so because their disease progressed; only 9% stopped due to treatment-related AEs.23
Tolerability, especially as patients define it, is increasingly important to payers, starting with Medicare. The Center for Medicare and Medicaid Innovation has announced that it will incorporate patient-reported outcomes (PROs) into the Oncology Care First model, the proposed successor to the Oncology Care Model.24 Advocates for including PROs in payment models are encouraging drug developers to broaden definitions of tolerability, to include quality-of-life data in trial designs.25
Its a straightforward idea: When patients can tolerate treatment, it improves their chances of survival. This is important, Tam said during ASCO. The longer you take the drug, the better your responses become.19
Author Information
Maggie L. Shaw is associate editor, The American Journal of Managed Care.
References
1. Erba HP. BTK inhibition in B-cell lymphomas: an overview of Bruton tyrosine kinase inhibition. Targeted Oncology. June 21, 2019. Accessed July 18, 2020. https://www.targetedonc.com/view/btk-lymphoma
2. Wyckoff AS. Dr. Brutons discovery set the stage for modern clinical immunology. American Academy of Pediatrics News. May 31, 2018. Accessed July 18, 2020. https://www.aappublications.org/news/2018/05/31/dyk053118
3. Buckley RH. [Commentary:] agammaglobulinemia, by Col. Ogden C. Bruton, MC, USA, Pediatrics, 1952;9:722-728. Pediatrics. 1998;102(suppl 1):213-215. https://pediatrics.aappublications.org/content/102/Supplement_1/213
4. Deane P. B cells: the antibody factories of the immune system. Life Extension Advocacy Foundation. August 22, 2017. Accessed July 18, 2020. https://www.lifespan.io/news/b-cells/
5. BTK gene: Bruton tyrosine kinase. US National Library of Medicine/Genetics Home Reference. Updated July 7, 2020. Accessed July 18, 2020. https://ghr.nlm.nih.gov/gene/BTK#
6. Bruton tyrosine kinase inhibitor. Science Direct. Accessed July 18, 2020. https://www.sciencedirect.com/topics/medicine-and-dentistry/bruton-tyrosine-kinase-inhibitor
7. BTK inhibitors. Drugs.com. Updated January 7, 2020. Accessed July 18, 2020. https://www.drugs.com/drug-class/btk-inhibitors.html
8. Ibrutinib. MedlinePlus. Updated May 15, 2019. Accessed July 19, 2020. https://medlineplus.gov/druginfo/meds/a614007.html
9. Imbruvica approval history. Drugs.com. Updated 2020. Accessed July 19, 2020. https://www.drugs.com/history/imbruvica.html
10. Berger JA. The evolving role of BTK inhibitors in treating chronic lymphocytic leukemia BTK inhibition: disease state effectiveness. Targeted Oncology. April 16, 2020. Accessed July 19, 2020. https://www.targetedonc.com/view/evolving-btk-cll?seriesVid=2
11. How does Imbruvica work? Imbruvica (ibrutinib). April 20, 2020. Accessed July 19, 2020. https://imbruvica.com/cll/how-does-imbruvica-work
12. Imbruvica. Chemocare. Accessed July 19, 2020. chemocare.com/chemotherapy/drug-info/imbruvica.aspx
13. Ghasoub R, Albattah A, Elazzazy S, et al. Ibrutinib-associated sever[e] skin toxicity: a case of multiple inflamed skin lesions and cellulitis in a 68-year-old male patient with relapsed chronic lymphocytic leukemia case report and literature review. J Oncol Pharm Pract. 2020;26(2):487-491. doi:10.1177/1078155219856422
14. Bennett C. Ibrutinib may impair natural killer cell cytotoxic activity, study suggests. Cancer Therapy Advisor. June 19, 2019. Accessed July 19, 2020. https://www.cancertherapyadvisor.com/home/cancer-topics/lymphoma/ibrutinib-for-mantle-lymphoma-mcl-may-impair-naturalcyto-toxic-activity/
15. Patel V, Balakrishnan K, Bibikova E, et al. Comparison of acalabrutinib, a selective Bruton tyrosine kinase inhibitor, with ibrutinib in chronic lymphocytic leukemia cells. Clin Cancer Res. 2017;23(14):3734-3743. doi:10.1158/1078-0432.CCR-16-1446
16. Garcia-Sanz R, Dimopoulos MA, Lee H-P, et al. Updated results of the ASPEN trial from a cohort of patients with MYD88 wild-type (MYD88WT) Waldenstrm macroglobulinemia (WM). J Clin Oncol. 2020;38(15 suppl; abstr e20056). doi:10.1200/JCO.2020.38.15_suppl.e20056
17. Tam CSL, Opat S, DSa S, et al. ASPEN: results of a phase III randomized trial of zanubrutinib versus ibrutinib for patients with Waldenstrm macroglobulinemia (WM). J Clin Oncol. 2020;38(15 suppl; abstr 8007). doi:10.1200/JCO.2020.38.15_suppl.8007
18. BeiGene presents updated head to head results from phase 3 trial of zanubrutinib vs. ibrutinib in patients with Waldenstrms macroglobulinemia at the 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Program. News release. BeiGene; May 29, 2020. Accessed August 3, 2020. https://www.globenewswire.com/news-release/2020/05/29/2040883/0/en/BeiGene-Presents-Updated-Head-to-Head-Results-from-Phase-3-Trial-of-Zanubrutinibvs-Ibrutinib-in-Patients-with-Waldenstrm-s-acroglobulinemiaat-the-2020-American-Society-of-Clini.html
19. Caffrey M. Zanubrutinib pulls away from ibrutinib in update, shows durable responses in Waldenstrom patients lacking key mutation. The American Journal of Managed Care. May 30, 2020. Accessed July 21, 2020. https://www.ajmc.com/conferences/asco-2020/zanubrutinib-pulls-away-from-ibrutinib-in-update-shows-durable-responses-in-waldenstrom-patients-lacking-key-mutation
20. Dr Constantine Tam discusses the benefits of zanubrutinib on cardiac effects. The American Journal of Managed Care. May 31, 2020. Accessed July 22, 2020. https://www.ajmc.com/conferences/asco-2020/dr-constantine-tam-discusses-the-benefits-of-zanubrutinib-on-cardiac-effects
21. Hershkovitz-Rokah O, Pulver D, Lenz G, Shpilberg O. Ibrutinib resistance in mantle cell lymphoma: clinical, molecular and treatment aspects. Br J Haematol. 2018;181(3):306-319. doi:10.1111/bjh.15108
22. Chronic lymphocytic leukemia. CancerWall. Accessed July 24, 2020. https://cancerwall.com/chronic-lymphocytic-leukemia-lifeexpectancy-symptoms/
23. Furman RR, Byrd JC, Own RG, et al. Safety of acalabrutinib (acala) monotherapy in hematologic malignancies: pooled analysis from clinical trials. J Clin Oncol. 2020;38(suppl 15; abstr 8064). doi:10.1200/JCO.2020.38.15_suppl.8064
24. Bekele B, Macher D, Ferguson S, et al. Emerging trends in oncology management. Avalere Health. June 2, 2020. Accessed July 31, 2020. https://avalere.com/insights/emerging-trends-in-oncology-management
25. Basch E, Campbell A, Hudgens S, et al. A Friends of Cancer research white paper: broadening the definition of tolerability in cancer clinical trials to better measure the patient experience. Friends of Cancer Research. October 24, 2018. Accessed July 31, 2020. https://www.focr.org/sites/default/files/Comparative%20Tolerability%20Whitepaper_FINAL.pdf
Excerpt from:
Second-Generation BTK Inhibitors Hit the Treatment Bullseye With Fewer Off-Target Effects - AJMC.com Managed Markets Network
- 8: Techniques of Molecular Genetics - Biology LibreTexts - January 23rd, 2024
- Molecular Genetics and Metabolism Reports - ScienceDirect - December 18th, 2022
- Molecular Genetics and Metabolism | Journal - ScienceDirect - December 18th, 2022
- Molecular clock - Wikipedia - December 2nd, 2022
- Molecular Structure of Nucleic Acids: A Structure for Deoxyribose ... - December 2nd, 2022
- Molecular Genetics School of Graduate Studies - University of Toronto - October 13th, 2022
- Molecular pathways of major depressive disorder converge on the synapse | Molecular Psychiatry - Nature.com - October 13th, 2022
- Can artificial intelligence help identify best treatments for cancers? LSU researchers say yes - The Advocate - October 13th, 2022
- Results for the fiscal year on June 30, 2022 - Yahoo Finance - October 13th, 2022
- From the journals: MCP - ASBMB Today - October 13th, 2022
- From cave-dweller scientist to Nobel laureate - The Tribune India - October 13th, 2022
- Animal Genetics Market - Know the Revenue and Profit-Sources of the Industry - openPR - October 13th, 2022
- Molecular and Cell Biology and Genetics - Master of Science / PhD ... - September 25th, 2022
- What does the future hold for COVID-19? - UCLA Health Connect - September 25th, 2022
- Farooq Kperogi: Lies and truth about Obi, Atiku, and Tinubu - Peoples Gazette - September 25th, 2022
- Atavistik Bio Announces Formation of Scientific Advisory Board - Business Wire - September 25th, 2022
- Scientific Advances Point to Improved Understanding of Radiation Exposure - Livermore Independent - September 25th, 2022
- 19 million to investigate bold ideas in bioscience research - EurekAlert - September 25th, 2022
- Machel, Iwer among full list of National Awardees - Trinidad Guardian - September 25th, 2022
- Newly Discovered Protein Connected to Alzheimers Disease Risk - Neuroscience News - September 25th, 2022
- The Lab Report: Sharma Lab studies biodiversity of arachnids - The Badger Herald - September 16th, 2022
- Environmental Scientist Jesse Ausubel to Receive 2022 Nierenberg Prize for Science in the Public Interest - Scripps Institution of Oceanography - September 16th, 2022
- Malaria vax promising, to be cheap too - The Hans India - September 16th, 2022
- Dayton Therapeutics Discovers New Therapeutic Uses of Satraplatin for Treatment of Rare Lymphomas - StreetInsider.com - September 16th, 2022
- JNCASRs novel molecule prevents obesity in mice - The Hindu - September 16th, 2022
- Research Fellow in the Department of Medical and Molecular Genetics job with KINGS COLLEGE LONDON | 308234 - Times Higher Education - September 8th, 2022
- Seven Queen's researchers elected to the Royal Society of Canada - Queen's University - September 8th, 2022
- Molecular Biology with an Industrial Placement Year BSc - India Education Diary - September 8th, 2022
- Whole Exome Sequencing Market Projected to Reach CAGR of 19.0% Forecast by 2029, Global Trends, Size, Share, Growth, Future Scope and Key Player... - September 8th, 2022
- Molecular prevalence and genetic diversity of Bartonella spp. in stray cats of zmir, Turkey - Parasites & Vectors - Parasites & Vectors - August 30th, 2022
- How light and temperature work together to affect plant growth - EurekAlert - August 30th, 2022
- Ancient Mummies' Lousy View of the Past - The Scientist - August 30th, 2022
- 'Gray blanket' over Australia: Genetics may have aided European rabbit invasion of continent in 1859, says study - Down To Earth Magazine - August 30th, 2022
- Meet the UNC Pembroke professor leading research on Alzheimers disease - The Robesonian - August 30th, 2022
- Massive Genome Study Informs the Biology of Reading and Language - Neuroscience News - August 30th, 2022
- People in the News at Gencove, IsoPlexis, HTG Molecular, More - GenomeWeb - August 30th, 2022
- Professor (with Head of Department potential), Department of Medical & Molecular Genetics job with KINGS COLLEGE LONDON | 304203 - Times Higher... - August 14th, 2022
- Kathy C. Cordes, a former Baltimore Sun artist who later worked at NASA's Space Telescope Institute, dies Baltimore Sun - Baltimore Sun - August 14th, 2022
- Discovery of the interactions between plants and arbuscular mycorrhizal fungi - EurekAlert - August 14th, 2022
- A new drug could repair stroke damage to memory and movement - Freethink - August 14th, 2022
- CDC Says Recent Flu Season Mild, Maybe Owing to COVID Precautions - Medscape - August 14th, 2022
- Study Using NanoStrings GeoMx Digital Spatial Profiler Featured on the Cover of Nature Genetics - BioSpace - August 14th, 2022
- New virus detected in China; here's everything you need to know about it - WCCO - August 14th, 2022
- Relief Therapeutics and Acer Therapeutics Announce that the European Commission Has Granted Orphan Drug Designation for ACER-001 in Maple Syrup Urine... - August 14th, 2022
- Psychiatry, Fraud, and the Case for a Class-Action Lawsuit - Mad In America - Mad in America - August 14th, 2022
- Scientists Grow Mouse Embryos Without Sperm Or Eggs - EverythingGP - August 14th, 2022
- The Pitfalls of Evolutionary Genomics - SciTechDaily - August 14th, 2022
- How a simple home DNA test unravelled the genetic code that could help prolong my life - The National - August 14th, 2022
- Graduate Research Officer job with UNIVERSITY OF WESTERN AUSTRALIA | 304277 - Times Higher Education - August 14th, 2022
- These Are the Degrees of the Future - Gizmodo - August 14th, 2022
- University of Chicago obituaries - University of Chicago - August 14th, 2022
- Letter: Abortion and social planning - Daily Herald - August 14th, 2022
- Postdoctoral Researcher, Seaweed Molecular Biology, Physiology and Genetics, Ryan Institute, School job with NATIONAL UNIVERSITY OF IRELAND, GALWAY |... - August 5th, 2022
- Researchers crack 30-year-old mystery of odour switching in worms - University of Toronto - August 5th, 2022
- 1st synthetic mouse embryos complete with beating hearts and brains created with no sperm, eggs or womb - Livescience.com - August 5th, 2022
- Rallybio Appoints Wendy K. Chung, M.D., Ph.D., to Its Board of Directors - Business Wire - August 5th, 2022
- Luke Goldman: Using eDNA to save the Atlantic cod - UMaine News - University of Maine - University of Maine - August 5th, 2022
- Duke Announces Winners of the 2022 DST Spark Seed Grants - Duke Today - July 27th, 2022
- WVXU: UC scientists are deep-freezing molecules. Here's why they're so excited about it - University of Cincinnati - July 27th, 2022
- Better Diagnosis and Treatment: Genetic Clues to Age-Related Macular Degeneration - SciTechDaily - July 27th, 2022
- Regeneron Announces the 2022 Winners of the Regeneron Prize for Creative Innovation - PR Newswire - July 27th, 2022
- Replay Launches with $55 Million Seed to Reprogram Biology by Writing and Delivering Big DNA - GlobeNewswire - July 27th, 2022
- How is Biotechnology revolutionising food and beverage industry? - The Statesman - July 27th, 2022
- ACP offers guidance on the ethical use of genetic testing and precision medicine - EurekAlert - July 27th, 2022
- Barbour Appointed Dean of The Graduate School and Vice Provost for Graduate Education - Duke Today - July 19th, 2022
- UC scientists are deep-freezing molecules. Here's why they're so excited about it - WVXU - July 19th, 2022
- Research Fellow, Molecular Biology / Recombinant Protein Production and Purification (Biol Sci) job with NATIONAL UNIVERSITY OF SINGAPORE | 301436 -... - July 19th, 2022
- UF researchers discover new way to inhibit virus that causes COVID-19 - University of Florida - July 19th, 2022
- Streamlined Genomic Testing Platforms Are Taking on A Bigger Role in Cancer Care - OncLive - July 19th, 2022
- Bachelor of Science in Biology - National University - July 19th, 2022
- Genes may influence our successes and failures in life, according to Professor Kathryn Paige Harden - ABC News - July 19th, 2022
- Lecturer for Department of Experimental Biology job with MASARYK UNIVERSITY | 301048 - Times Higher Education - July 19th, 2022
- Lecturer in Biology (Education Focused) job with UNIVERSITY OF SYDNEY | 300815 - Times Higher Education - July 19th, 2022
- People's University Is All About Dinosaurs This Summer - Wheeling Intelligencer - July 19th, 2022
- Radiologists hope to use AI to improve readings - University of Miami: News@theU - July 19th, 2022
- Rare Disease Genetic Testing Market 2022 Emerging Trends, Comprehensive Study With Top Companies and Key Players till 2030 - Taiwan News - July 11th, 2022
- Proteases implicated in ulcerative colitis - ASBMB Today - July 11th, 2022
- Cancer has been a scourge for centuries, advances in science have made the disease far less intractable - The Indian Express - July 11th, 2022
- Scientists discover key genes behind insect migrations - EurekAlert - July 11th, 2022
- Neuroimaging Techniques and What a Brain Image Can Tell Us - Technology Networks - July 11th, 2022